MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14712598.2024.2442452

Медицинская библиотека · Expert opinion on biological therapy · 2024

Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project.

Lopes Sara, Servadio Michela, Spini Andrea, L'Abbate Luca, Ingrasciotta Ylenia, Giometto Sabrina, Lucenteforte Ersilia, Leoni Olivia, Zanforlini Martina, Ancona Domenica, Stella Paolo, Puccini Aurora, Sapigni Ester, Rossi Paola, Ejlli Lucian, Balducci Francesco, Mangano Antea Maria Pia, Ledda Stefano, Carta Paolo, Scarpelli Rita Francesca, De Sarro Giovambattista, Massari Marco, Spila Alegiani Stefania, Addis Antonio, Trifirò Gianluca, Belleudi Valeria

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Monitoring biologic drug therapy during pregnancy in women with immune-mediated inflammatory diseases (IMIDs) is crucial to ensure treatments align with evidence-based practices.

RESEARCH DESIGN AND

METHODS

A retrospective cohort study based on healthcare claims data from eight Italian regions was conducted, analyzing deliveries between 2009 and 2021. The study included women receiving biologic drugs within nine months before their last menstruation. Exposures to biologics, conventional disease-modifying anti-rheumatic drugs (DMARDs) and symptom-relieving medications were assessed in the trimesters (T) before, during and after pregnancy. Factors influencing biologic treatment persistence during pregnancy were analyzed.

RESULTS

A cohort of 1,763 deliveries was considered. Biologic drugs were prescribed for rheumatic (33.6%), dermatological (32.6%), and gastrointestinal diseases (28.4%). Biologic use declined during pregnancy (TI = 37.3%; TII = 17.6%; TIII = 11.3%), increasing again postpartum. During pregnancy, there was increased use of symptom-relieving medications for rheumatic diseases and DMARDs for gastrointestinal diseases. Factors associated with continued biologic treatment included being older than 35 years and the region of delivery.

CONCLUSIONS

This study found a decrease in biologics drug use during pregnancy and highlights the necessity for personalized therapeutic approaches. Geographic variations in biologic drug use emphasize the need for educational initiatives about the risk-benefit profiles of these therapies during pregnancy.

Для цитирования: Lopes Sara, Servadio Michela, Spini Andrea, L'Abbate Luca, Ingrasciotta Ylenia, Giometto Sabrina, Lucenteforte Ersilia, Leoni Olivia, Zanforlini Martina, Ancona Domenica, Stella Paolo, Puccini Aurora, Sapigni Ester, Rossi Paola, Ejlli Lucian, Balducci Francesco, Mangano Antea Maria Pia, Ledda Stefano, Carta Paolo, Scarpelli Rita Francesca, De Sarro Giovambattista, Massari Marco, Spila Alegiani Stefania, Addis Antonio, Trifirò Gianluca, Belleudi Valeria. Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project.. Expert opinion on biological therapy. 2024. DOI: 10.1080/14712598.2024.2442452.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.